# PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

> **NCT06074692** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 86 (estimated)

## Conditions studied

- Sarcoma
- Sarcoma,Soft Tissue
- Sarcoma of Bone

## Interventions

- **COMBINATION_PRODUCT:** Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT06074692
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06074692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06074692, "PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06074692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*